	2012 Mar 31	2013 Mar 31	2014 Mar 31	C 2015 Mar 31	R 2016 Mar 31	2017 Mar 31	2018 Mar 31	2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M PR	12M PR	12M PR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Total Revenue	2,016	2,495	3,126	3,741	4,925	5,688	6,422	7,357	8,344	8,865	10,634	11,599	12,668	12,965	14,712
Cost of Operating Revenue	895	1,133	1,475	1,833	2,134	2,436	2,758	3,255	3,672	3,864	4,568	5,241	5,327	5,202	5,475
Gross Profit	1,121	1,362	1,651	1,908	2,790	3,252	3,664	4,102	4,672	5,001	6,066	6,358	7,340	7,763	9,237
Gross Margin	55.6	54.6	52.8	51.0	56.7	57.2	57.1	55.8	56.0	56.4	57.0	54.8	57.9	59.9	62.8
Total Operating Expenses	1,662	2,159	2,741	3,312	4,132	4,788	5,504	6,393	7,038	7,196	8,862	10,215	10,681	10,783	12,089
Operating Profit	353	336	385	429	793	900	918	965	1,307	1,669	1,773	1,384	1,987	2,182	2,623
Operating Margin	17.5	13.5	12.3	11.5	16.1	15.8	14.3	13.1	15.7	18.8	16.7	11.9	15.7	16.8	17.8
Financing Income/(Expense) - Net	68	62	32	41	57	58	22	-9	-30	90	53	-5	141	273	-161
Profit before Taxes	433	402	430	451	928	965	926	955	1,260	1,842	1,844	1,305	2,023	2,527	2,871
Income Taxes	28	18	-5	59	176	60	288	181	110	224	164	298	212	311	518
Profit after Tax	407	384	435	392	742	892	631	761	1,127	1,585	1,646	984	1,796	2,165	2,302
PAT Margin	20.2	15.4	13.9	10.5	15.1	15.7	9.8	10.3	13.5	17.9	15.5	8.5	14.2	16.7	15.6
EPS - Basic - ex Extraordinary Items	34.00	32.10	36.41	32.75	62.02	74.61	52.77	63.61	94.26	132.57	137.63	82.31	150.19	181.11	192.51
EPS - Diluted - ex Extraordinary Items	34.00	32.10	36.41	32.75	62.02	74.61	52.77	63.61	94.26	132.57	137.63	82.31	150.19	181.11	192.51
EBIT	353	336	385	429	793	900	918	965	1,307	1,669	1,773	1,384	1,987	2,182	2,623
EBITDA	382	376	437	500	886	1,001	1,061	1,158	1,560	1,943	2,077	1,695	2,286	2,539	3,005
EBITDA Margin	19.0	15.1	14.0	13.4	18.0	17.6	16.5	15.7	18.7	21.9	19.5	14.6	18.0	19.6	20.4

Balance Sheet

Abridged

Understanding Balance Sheet

Alkem Laboratories Ltd. balance sheet covering assets, liabilities, equity and borrowings across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	C 2012 Mar 31	C 2013 Mar 31	C 2014 Mar 31	R 2015 Mar 31	R 2016 Mar 31	C 2017 Mar 31	2018 Mar 31	C 2019 Mar 31	R 2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Source:	PR	PR	PR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	AR	PRESS
Total Current Assets	1,312	2,156	1,602	2,347	2,769	2,917	3,915	4,216	5,506	6,929	8,435	8,730	10,412	10,946	12,211
Long-Term Investments	299	410	338	654	477	659	279	132	133	159	880	484	374	1,266	2,312
Property Plant & Equipment - Net	674	896	980	1,084	1,203	1,694	2,254	2,599	2,774	2,706	2,766	2,514	2,557	2,863	3,229
Total Non-Current Assets	2,154	2,116	2,714	2,992	2,766	3,651	3,750	3,992	4,440	4,590	5,634	5,027	5,163	6,745	8,662
Total Assets	3,466	4,272	4,317	5,339	5,535	6,568	7,666	8,208	9,946	11,519	14,069	13,757	15,575	17,691	20,873
Total Current Liabilities	1,124	1,735	1,406	2,017	1,538	1,690	2,383	2,218	3,245	3,604	4,805	3,707	3,995	3,965	4,783
Long Term Debt	309	256	232	39	126	182	131	231	159	98	76	70	229	578	869
Total Non-Current Liabilities	528	366	332	119	210	295	297	419	392	357	417	614	866	1,292	1,741
Total Liabilities	1,652	2,100	1,737	2,136	1,748	1,985	2,680	2,636	3,637	3,961	5,222	4,322	4,861	5,257	6,524
Total Shareholders' Equity	1,814	2,172	2,579	3,119	3,692	4,468	4,864	5,439	6,161	7,377	8,638	9,045	10,312	11,985	13,820
Minority Interest	0	-	-	85	95	115	122	133	148	181	209	390	402	449	529
Total Equity	1,815	2,172	2,579	3,203	3,787	4,583	4,985	5,572	6,309	7,558	8,847	9,435	10,714	12,434	14,349
Total Liabilities & Equity	3,466	4,272	4,317	5,339	5,535	6,568	7,666	8,208	9,946	11,519	14,069	13,757	15,575	17,691	20,873

Cash Flow

Abridged

Understanding Cash Flow Statement

Alkem Laboratories Ltd. cash flow statement covering operating, investing and financing activities across annual and quarterly periods.

Consolidated

Standalone

Annual

Interim

	2012 Mar 31	2013 Mar 31	2014 Mar 31	C 2015 Mar 31	R 2016 Mar 31	C 2017 Mar 31	C 2018 Mar 31	C 2019 Mar 31	2020 Mar 31	2021 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31	2026 Mar 31

Period length: Source:	12M PR	12M PR	12M PR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M AR	12M PRESS
Operating CF bef Changes in Working Cap	334	339	436	347	803	793	873	909	1,218	1,631	1,714	1,412	2,148	2,394	2,582
Working Capital - Increase/(Decrease)	-145	-183	-36	-12	10	-263	-573	-140	-647	-341	-545	327	-52	-214	-415
Net CF from Operating Activities	190	156	400	335	813	531	300	769	571	1,290	1,169	1,739	2,096	2,180	2,167
Capital Expenditures - Net	248	233	100	135	253	634	677	527	348	184	328	230	187	635	487
Net CF from Investing Activities	-333	-562	149	-326	43	-409	-446	-360	-792	-1,077	-1,533	-34	-1,248	-1,647	-1,995
Dividends Paid - Cash - Total	21	52	32	57	185	86	218	219	440	335	422	530	540	505	614
Stock - Issuance/(Retirement) - Net	-	-	-	-	-	-	0	-	-	-	-	161	-	-	-
Debt - LT & ST - Issuance/(Retirement) - Total	65	487	-477	84	-671	12	357	-106	584	117	842	-1,302	-513	-226	208
Net Cash Flow from Financing Activities	44	435	-509	28	-856	-74	140	-324	144	-218	420	-1,670	-1,054	-730	-380
Free Cash Flow to Equity	6	410	-177	284	-111	-92	-20	136	807	1,222	1,682	207	1,396	1,320	1,888
Free Operating CF net dividend	-81	-130	264	140	372	-200	-602	21	-232	760	408	977	1,296	1,000	936
Free Operating CF	-60	-78	296	197	556	-114	-384	240	208	1,095	830	1,506	1,837	1,504	1,550

Business Segment Analysis

FY End:

Mar 25

Alkem Laboratories Ltd. business segment breakdown covering revenue, operating income and assets across key divisions for the selected financial year.

Capex

Pharmaceuticals (100.0%)₹ 675.62 Cr

Revenue / Sales

Pharmaceuticals (100.0%)₹ 12,964.52 Cr

Assets

Pharmaceuticals (100.0%)₹ 17,691.10 Cr

Operating Income

Pharmaceuticals (100.0%)₹ 2,181.54 Cr

Regional Segment Analysis

FY End:

Mar 25

Alkem Laboratories Ltd. geographic revenue split showing domestic and international market performance across revenue and income for the selected financial year.

Revenue / Sales

India (Country) (70.5%)₹ 9,143.57 CrUnited States of America (19.1%)₹ 2,481.76 CrOther Countries (10.3%)₹ 1,339.19 Cr

Historical Segment Analysis

Track how Alkem Laboratories Ltd. segment contributions have evolved over multiple financial years to see which divisions are growing, shrinking or gaining strategic importance.

Capex

Sales

Assets

Operating Income

Business

Regional

Business

	2011 Mar 31	2012 Mar 31	2013 Mar 31	2014 Mar 31	2015 Mar 31	2016 Mar 31	2022 Mar 31	2023 Mar 31	2024 Mar 31	2025 Mar 31

Pharmaceuticals	109	151	261	155	295	231	339	233	259	676
Investing Business	0	0	0	0	0	0	-	-	-	-
Unallocable	-	-	0	0	0	0	-	-	-	-

Frequently Asked Questions

What is the revenue of Alkem Laboratories Ltd.?

The latest trailing twelve month revenue of Alkem Laboratories Ltd. is ₹ 14,712.30 Cr, reflecting a 1-year growth of 13.48% and a 3-year CAGR of 8.25%. Annual and quarterly revenue trends are available in the Income Statement section.

What is the net profit of Alkem Laboratories Ltd.?

The latest trailing twelve month net profit (PAT) of Alkem Laboratories Ltd. is ₹ 2,301.80 Cr, with a 3-year earnings CAGR of 32.74%. Detailed profit history across annual and quarterly periods is in the Income Statement section.

What is the EBITDA of Alkem Laboratories Ltd.?

The trailing twelve month EBITDA of Alkem Laboratories Ltd. is approximately ₹ 2,623.14 Cr (based on an operating margin of 17.83%). EBITDA reflects core operating profitability before interest, taxes, depreciation and amortisation.

What is the EPS of Alkem Laboratories Ltd.?

The trailing twelve month Earnings Per Share (EPS) of Alkem Laboratories Ltd. is 192.51. EPS trends across annual and quarterly periods are visible in the Income Statement section.

What is the debt level of Alkem Laboratories Ltd.?

The debt-to-equity ratio of Alkem Laboratories Ltd. stands at 0.15. The interest coverage ratio is 16.32x, reflecting the company's ability to service debt from operating earnings. The full breakdown of total borrowings is in the Balance Sheet section.

What is the book value per share of Alkem Laboratories Ltd.?

The estimated book value per share of Alkem Laboratories Ltd. is 1,155.87 (derived from a P/B ratio of 4.89 and market price of ₹ 5,650.00), reflecting the net asset value attributable to each share. See the Balance Sheet section for a full breakdown.

What is the cash flow from operations of Alkem Laboratories Ltd.?

The trailing twelve month operating cash flow of Alkem Laboratories Ltd. is ₹ 2,167.26 Cr. Annual and quarterly cash flow data is available in the Cash Flow section of the Statements tab.

Does Alkem Laboratories Ltd. report consolidated or standalone financials?

Alkem Laboratories Ltd. reports consolidated financials. You can toggle between consolidated and standalone views using the switch at the top of each statement section.